"Israelbased Neuronix which has developed a noninvasive medical device to help to treat Alzheimers disease expects the system to be approved by the U.S. Food  Drug Administration in late . The device which combines electromagnetic stimulation with computerbased cognitive training is already approved for use in Europe Israel and several Asian countries such as Singapore.  You stimulate the brain on a biological level as well as on a cognitive level Neuronix CEO Eyal Baror told Reuters saying this double approach created longerlasting benefits.  The device which consists of a chair containing an electronic system and software in the back and a coil placed at the head has been tested on mild to moderate Alzheimers patients who suffer from dementia but are not totally dependent.  The system is in trials at Harvard Medical SchoolBeth Israel Deaconess Medical Centre. Patients are treated for one hour a day five days a week over six weeks.  We see improvement lasting for  months and the good thing is that patients can return and undergo treatment again Baror said. If out of  years the patients have left to live we can keep them at home in a relatively mild state of the disease for three four five years its a lot.  According to Alvaro PascualLeone director of the hospitals BerensonAllen Centre for Noninvasive Brain Stimulation brain stimulation  or transcranial magnetic stimulation  involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.   The application in Alzheimers disease and in combination with cognitive training is novel PascualLeono said in a phone interview from Boston.  About  percent of patients experience a mild headache but there are no longterm negative effects he said.  PascualLeone who is principal investigator in the Harvard trial said that of  patients in the study six received the real treatment and all showed cognitive improvement. Their improvement was significantly more than the average seen in patients taking just medication he said.  The studys results will be submitted for publication in the coming weeks and a followup study on  patients is planned.  Neuronix received European approval several months ago and has installations in the UK and Germany. In Israel a few dozen patients are being treated with the device.  The U.S. trials are expected to run till the end of . Neuronix is also running a trial in Israel for preAlzheimers patients.  The company expects to sell half a dozen systems in the second half of  and three dozen in . In Israel the treatment costs .  Our target for becoming profitable is in parallel to entering the U.S. market around  Baror said.  Neuronix has raised  million from private individuals as well as in grants from the Israeli Chief Scientists Office and is exploring options to raise more money in the coming year including the possibility of going public."